Avastin Makes Headway Into Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche unveils positive metastatic RCC data from the highly anticipated AVOREN study at American Society of Clinical Oncology meeting.
You may also be interested in...
Genentech Plans Avastin Breast Cancer Resubmission In August
Company expects a six-month review for the supplemental claim, setting early 2008 for potential FDA approval.
Genentech Plans Avastin Breast Cancer Resubmission In August
Company expects a six-month review for the supplemental claim, setting early 2008 for potential FDA approval.
GlaxoSmithKline’s Pazopanib Shows Positive Results In Renal Cell Carcinoma
Preliminary analysis shows a 73 percent total disease control rate, according to presentation at ASCO.